Eli Lilly And Co (NYSE:LLY) has been given a $117.00 price target by equities research analysts at JPMorgan Chase & Co. in a report issued on Wednesday, The Fly reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s price objective would suggest a potential upside of 9.60% from the company’s previous close.

A number of other research analysts also recently weighed in on the stock. Barclays reissued an “overweight” rating and set a $112.00 target price (up from $107.00) on shares of Eli Lilly And Co in a research report on Tuesday, September 18th. Cantor Fitzgerald set a $110.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a research note on Monday, September 17th. TheStreet cut shares of Eli Lilly And Co from a “b” rating to a “c+” rating in a research note on Friday, August 24th. ValuEngine upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. Finally, Morgan Stanley upped their price target on shares of Eli Lilly And Co from $93.00 to $102.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 31st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $102.06.

Shares of Eli Lilly And Co stock traded up $1.05 on Wednesday, reaching $106.75. 48,120 shares of the company traded hands, compared to its average volume of 3,395,860. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $107.84. The company has a market capitalization of $113.40 billion, a P/E ratio of 24.89, a P/E/G ratio of 1.85 and a beta of 0.28. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The firm had revenue of $6.36 billion during the quarter, compared to the consensus estimate of $6.05 billion. During the same period in the prior year, the firm earned $1.11 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. equities analysts expect that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 6,000 shares of the stock in a transaction that occurred on Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total value of $637,860.00. Following the sale, the senior vice president now directly owns 55,224 shares in the company, valued at approximately $5,870,863.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Eli & Co Lilly sold 6,865 shares of the stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $14.58, for a total transaction of $100,091.70. Following the completion of the sale, the insider now owns 3,864,409 shares in the company, valued at $56,343,083.22. The disclosure for this sale can be found here. Insiders have sold a total of 1,706,944 shares of company stock worth $167,978,247 over the last 90 days. 0.11% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of LLY. Victory Capital Management Inc. lifted its stake in Eli Lilly And Co by 3.8% in the 1st quarter. Victory Capital Management Inc. now owns 19,693 shares of the company’s stock worth $1,524,000 after purchasing an additional 727 shares in the last quarter. TCW Group Inc. lifted its stake in Eli Lilly And Co by 3.0% in the 1st quarter. TCW Group Inc. now owns 37,253 shares of the company’s stock worth $2,882,000 after purchasing an additional 1,079 shares in the last quarter. Pinnacle Associates Ltd. lifted its stake in Eli Lilly And Co by 1.4% in the 1st quarter. Pinnacle Associates Ltd. now owns 54,058 shares of the company’s stock worth $4,182,000 after purchasing an additional 742 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Eli Lilly And Co by 1.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,906,115 shares of the company’s stock worth $147,472,000 after purchasing an additional 36,428 shares in the last quarter. Finally, First Allied Advisory Services Inc. lifted its stake in Eli Lilly And Co by 15.4% in the 1st quarter. First Allied Advisory Services Inc. now owns 27,874 shares of the company’s stock worth $2,159,000 after purchasing an additional 3,710 shares in the last quarter. Institutional investors and hedge funds own 76.51% of the company’s stock.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Buyback

The Fly

Analyst Recommendations for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.